Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure

被引:56
作者
Avorn, Jerry [1 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02120 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2013年 / 309卷 / 13期
关键词
D O I
10.1001/jama.2013.623
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:1349 / 1350
页数:2
相关论文
共 8 条
[1]
[Anonymous], 2012, JANSS BRIEF DOC TMC2
[2]
Carome M., 2012, COMMUNICATION
[3]
Drug-review deadlines and safety problems [J].
Carpenter, Daniel ;
Zucker, Evan James ;
Avorn, Jerry .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13) :1354-1361
[4]
Cox, 2012, COMMUNICATION
[5]
Hirschler Ben., 2012, REUTERS
[6]
Drug Development for Neglected Diseases - The Trouble with FDA Review Vouchers [J].
Kesselheim, Aaron S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (19) :1981-1983
[7]
Developing drugs for developing countries [J].
Ridley, DB ;
Grabowski, HG ;
Moe, JL .
HEALTH AFFAIRS, 2006, 25 (02) :313-324
[8]
US Food and Drug Administration, 2012, BRIEF PACK NDA 204 3